Advicenne SA
3MM
Company Profile
Business description
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
Contact
2, rue Briconnet
NimesF-30 000
FRAT: +33 466055420
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.00 | 2.50 | 0.03% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,409.37 | 181.66 | -0.77% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,620.38 | 211.92 | 0.83% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 54,399.08 | 1,670.36 | 3.17% |
| NZX 50 Index | 13,133.13 | 34.30 | 0.26% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,705.60 | 1.20 | 0.01% |
| SSE Composite Index | 4,105.85 | 9.25 | 0.23% |